VRTXVertex Pharmaceuticals Incorporated

Vertex treats cystic fibrosis with near-monopoly economics and uses the money to build a second franchise: pain relief without opioids.

Cystic fibrosis is a rare inherited disease, and the company found medicines that act on its cause rather than its symptoms. Competitors in that niche are practically absent, patients take the therapy for life, and pricing is high — a combination producing exceptional margins and predictable revenue.

The flip side is concentration: one disease and one drug class supply nearly all revenue. The investor's question is therefore always the same: what replaces that pillar when patent protection ends.

The answer being built is a new class of painkiller that works without addiction risk, and a cell therapy for sickle-cell disease developed with CRISPR Therapeutics. Both could open markets an order of magnitude wider than a rare disease, and both carry the industry's usual trial risk. The company pays no dividend.